Here’s why these three cannabis stocks are in better shape than most others in the market. Take a deeper look into GW Pharmaceuticals, Insys Therapeutics, and Aphria.
On May 23, 2017, Hound Labs Inc., a marijuana breathalyzer company in Oakland, announced that it has closed its Series B round of financing with $8.1 million from Benchmark, a California-based venture capital firm that has made successful early-stage investments in companies like Uber and Snapchat, among others.
Last week, two marijuana stocks skyrocketed by a double-digit percentage. Let’s take a closer look at the possible “why” behind these moves.
On May 19, 2017, the U.S. Securities and Exchange Commission announced the temporary suspension of two marijuana stocks that trade on the OTC Markets, with both orders of suspension related to the companies neglecting to provide accurate and up-to-date information.
The marijuana industry, and marijuana stock investors for that matter, have been expanding by leaps and bounds over the past two decades. One good way to keep this up is through university-based clinical studies. Studies like these really fan the flame of what might be possible with cannabis-based medicines.
On May 19, 2017, Beleave Inc. (CNX:BE) announced that its subsidiary, First Access Medical Inc., had been awarded a cultivation license from Health Canada, prompting the Canadian cannabis stock to rise 7.62% on Friday.
The questions surrounding marijuana legalization have pushed many to wonder about the possibility of a marijuana stock bubble. And for good reason.
Countries around the globe are embracing legal medicinal or recreational cannabis, and the industry is reacting accordingly.
While investors holding for the past year have still made a positive return, there may not be much room left for marijuana companies’ shares to run higher.
Today we’re going to share seven essential tips that will help you save both time and money and invest in cannabis stocks as profitably as possible.
The recently debuted marijuana stock ETF, the Horizons Medical Marijuana Life Sciences ETF, has lost value for those who’ve decided to take the plunge.
A major Canadian medical marijuana player, Canopy Growth is a producer and retailer of medical cannabis products and oils in our neighbor to the north. It’s also the only other marijuana stock other than GW Pharmaceuticals to bear a $1 billion valuation.
As of April 13, 2017, more than 10.4 million shares of Insys Therapeutics (NASDAQ: INSY) were sold short. That’s 44% of the marijuana stock’s float. Investors have clearly bet big against Insys, anticipating that the stock will sink.
Canopy Growth Corp.’s now down approximately 36% since my warning that the stock could be heading for a correction that would be triggered by the banned pesticides scandal.
The MMJ Phytotech Ltd share price has been a big mover in morning trade following the release of a positive announcement.
Marijuana stocks are extremely risky. But, if things go right for these pot stocks over the next two to three years, they could be a steal for investors.
With multiple companies showing returns of more than 100%, you have what has turned into one of the more attractive sectors for investors in 2017. But is this the right move? Are marijuana stocks worth it? Most importantly, is now the time to invest in marijuana stocks?
Here’s a pot stock that should prove immune to the adverse political winds emanating from the nation’s capital as marijuana is transitioning in the public eye.
Since then the industry has exploded, and the number of cannabusinesses to go public have soared. Here are five cannabis stocks worth watching this week.
The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the United States and Canada, decreased 9% in April due primarily to heavy losses in the United States.
The marijuana industry is the hottest thing since sliced bread, and marijuana stocks are thriving. Here’s a quick rundown of the largest players.
Can marijuana stocks keep going higher? The answer could depend more on the laws of supply and demand than current U.S. laws.
You definitely don’t want to bet the family farm on such a speculative investment like Aurora Cannabis Inc., but there’s a substantial amount of upside if you don’t mind the large amount of risk.
With two marijuana stocks already sporting market caps over $1 billion, one of these four pot stocks is likely to be next.
After an Ottawa ban on celebrity endorsements of marijuana products, Snoop Dogg will not be able to explicitly promote Canopy’s Tweed-branded products.
Aphria Inc (TSE:APH) is now the front-runner in the race to hit the billion-dollar valuation mark.
Three Canadian medical cannabis companies, which have been expanding their growth operations like crazy over the past couple of quarters, could be in line for significant sales growth if Trudeau’s legislation passes.
On April 19, 2017, the California Supreme Court Committee on Judicial Ethics Opinions advised judges in California that holding a financial interest in any marijuana-related venture, whether medical or recreational, would violate the California Code of Judicial Ethics.
Prime Minister Justin Trudeau recently introduced legislation to legalize use of recreational marijuana in Canada. While legalization should help Canadian marijuana providers, could it also provide a boost to U.S. marijuana stocks?
Here are 4 top stocks in the growing medical marijuana industry that have a tremendous amount of potential for investors.
On April 20, 2017, Cowen and Company, a leading Wall Street investment bank, issued a report that shows the accelerated adoption of cannabis pressuring alcohol volumes, with beer most at risk.
There is an opportunity for excess profits in the Canadian marijuana industry as the market is now in a position to expand at a very high rate, as Canadians have received confirmation that the potential legalization will become a reality.
These 3 marijuana stocks make for some of the best investments in the cannabis industry for risk-averse investors.
These 5 marijuana stocks lost a combined $193 Million in 2016. Though they’re some of the top performers, they’re also among the companies losing the most money on an annual basis.
As Canada heads toward legalization of marijuana, Alberta producer Aurora Cannabis is focused on expansion with ambitions to raise a $160-million “war chest” from investors who are anxious to profit from what is expected to be a multibillion industry.
On Thursday, April 13, 2017, Canada made headlines with its official introduction of legislation to legalize recreational cannabis in the country by July 2018. While the country’s announcement has major national and international implications, cannabis stocks in Canada took a downturn upon hearing the news.
Insiders with two of Canada’s largest marijuana companies are cashing in on the industry’s reefer madness before the country introduces its plans for legalized recreational pot.
On April 12, 2017, Flowhub, a seed-to-sale cannabis compliance platform, announced that it had closed an oversubscribed Series A offering of $3.25 million, with Green Lion Partners and Phyto Partners leading this round of financing.
Aphria Inc. has been soaring since its graduation to the TSX last month. The company now has a $1.1 billion market cap and could pass Canopy Growth Corp. with its $1.74 billion market cap over the next few months. There’s no question Canopy stock has slowed down when compared to its peers like Aphria and Aurora Cannabis Inc
MJIC Inc. has added five new companies to the U.S. Marijuana Index as a result of its quarterly rebalancing.
While shares have backed off the 52 week highs, Aurora Cannabis is making another run towards the highs as investor enthusiasm increases over recreational marijuana legalization in Canada. Here’s the insider scoop and why we like Aurora Cannabis Inc.
While the Canadian Marijuana Index dipped slightly in March due to federal uncertainties, the Canadian public markets have bounced back today on the news of recreational marijuana legislation being introduced in Canada’s House of Commons this Thursday, April 13, 2017.
Medical marijuana remains the safest investment route — if you’re forced to choose one — so here’s a brief rundown of the cannabinoid-based drugs working their way through clinical and preclinical trials.
Although marijuana stocks have skyrocketed in the last couple of years, many investors have been understandably leery of jumping on board. Check out why investors might like these three stocks that don’t fit the mold of most marijuana stocks.
This past week brought a first for the investment world — a medical marijuana electronic-traded fund (ETF) made its debut.
Attorney General Jeff Sessions issued a memo on April 5, 2017, outlining the mission of the U.S. Department of Justice’s Task Force on Crime Reduction and Public Safety, including the creation of a subcommittee to review marijuana enforcement policies, and it did not go unnoticed by public market participants.
There are very few industries generating as much buzz as the medical and recreational marijuana markets are these days. With legislation across the world generally trending toward the legalization—or at least decriminalization of the drug—growth potential is strong, with investors seeking out “the best marijuana stocks to buy 2017.”
Medical marijuana producer Aphria Inc. is expanding into the lucrative U.S. market with an initial $25 million investment to set up shop in Florida, which recently legalized pot for medical use.
The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the United States and Canada, decreased 2% in March as losses in Canada overtook modest gains in the U.S.
U.S. real estate values are blazing, at least that is in the parts of the country where the sale of marijuana is now legal.